Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Mark G. Gomez CO- Founder Canna Ventures Group LLC $MNMD

<< Previous

Bullboard Posts

Next >>

Post by HampsStockstaron Jun 26, 2021 2:11am

540 Views

Post# 33455395

Mark G. Gomez CO- Founder Canna Ventures Group LLC $MNMD

Gomez was quoted on Bloomberg radio as saying "psychedelic & mushroom space could see 5-10x returns from current levels". And cited $MNMD, $CLXP $LRSV $ATAI as his current favorites in the sector. Friday 25th $MNMD strong after recently added to Russell also the Peter Thiel back $ATAI IPO bring alot of attention to mushroom / psychedelic sp

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity